Multicenter, randomized phase II study of neoadjuvant pembrolizumab plus chemotherapy and chemoradiotherapy in esophageal adenocarcinoma (EAC).

Manish A. Shah,Khaldoun Almhanna,Syma Iqbal,Prashant V. Thakkar,Bryan J. Schneider,Rhonda K. Yantiss,Yiru Wu,Emma Futamura,Jeffrey L. Port,Cathy F. Spinelli,Sandipto Sarkar,Paul J. Christos,Gagandeep Brar,Doron Betel,Nicholas J. Sanfilippo,Nasser K. Altorki

Multicenter, randomized phase II study of neoadjuvant pembrolizumab plus chemotherapy and chemoradiotherapy in esophageal adenocarcinoma (EAC).

2021

Manish A. Shah
Khaldoun Almhanna
Syma Iqbal
Prashant V. Thakkar
Bryan J. Schneider
Rhonda K. Yantiss
Yiru Wu
Emma Futamura
Jeffrey L. Port
Cathy F. Spinelli
Sandipto Sarkar
Paul J. Christos
Gagandeep Brar
Doron Betel
Nicholas J. Sanfilippo
Nasser K. Altorki

4005Background: Recent transformative studies in the treatment of EAC support adjuvant nivolumab for patients with residual disease following neoadjuvant chemoradiotherapy (CRT) (Checkmate 577) and...

Keywords:

Medicine
Chemoradiotherapy
Internal medicine
Nivolumab
Pembrolizumab
Chemotherapy
neoadjuvant chemoradiotherapy
Phases of clinical research
Oncology
Adjuvant
esophageal adenocarcinoma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations